Skip to content
10-Q

Quarterly Report

Oric Pharmaceuticals, Inc. ORIC

0001193125-26-204047

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 103.52M sh
Shares Diluted Q1 2026 · Mar 31, 2026 105.47M sh
Shares Diluted Q1 2026 · Mar 31, 2025 71.04M sh
Capex Q1 2026 · Mar 31, 2026 $2K
Capex Q1 2026 · Mar 31, 2025 $387K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$32.44M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$32.53M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $56.4M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $45.67M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $49.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $415.56M
Stockholders Equity Q1 2026 · Dec 31, 2025 $384.36M
Stockholders Equity Q1 2026 · Mar 31, 2025 $219.74M
Stockholders Equity Q1 2026 · Dec 31, 2024 $243.12M
Current Liabilities Q1 2026 · Mar 31, 2026 $17.77M
Current Liabilities Q1 2026 · Dec 31, 2025 $20.42M
Total Liabilities Q1 2026 · Mar 31, 2026 $21.21M
Total Liabilities Q1 2026 · Dec 31, 2025 $24.53M
Current Assets Q1 2026 · Mar 31, 2026 $290.23M
Current Assets Q1 2026 · Dec 31, 2025 $288.47M
Total Assets Q1 2026 · Mar 31, 2026 $436.76M
Total Assets Q1 2026 · Dec 31, 2025 $408.89M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.34
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.34
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $8.18M
Sga Expense Q1 2026 · Mar 31, 2025 $8.08M
Net Income Q1 2026 · Mar 31, 2026 −$35.77M
Net Income Q1 2026 · Mar 31, 2025 −$30.02M
Operating Income Q1 2026 · Mar 31, 2026 −$39.62M
Operating Income Q1 2026 · Mar 31, 2025 −$32.72M